Working… Menu
Trial record 34 of 46 for:    disulfiram

Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00312819
Recruitment Status : Completed
First Posted : April 11, 2006
Last Update Posted : August 31, 2010
Augusta Hospital, Berlin
Information provided by:
Hadassah Medical Organization

Brief Summary:
Recent studies in laboratory animals demonstrate the ability of disulfiram to significantly inhibit the growth and metastasis of a mouse model of lung cancer. Work with cells in vitro support the idea that this inhibition is mainly due to the inhibition of angiogenesis - the formation of new blood vessels in the tumor. Furthermore, it was found out that the best effect has been obtained when disulfiram has been used not at the highest dose but at an optimal dose, which is smaller. Thus, this trial will assess the addition of disulfiram to chemotherapy in non-small cell lung cancer (NSCLCA).

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: chemotherapy +/- disulfiram Phase 2 Phase 3

Detailed Description:

Metastatic non small cell lung cancer remains a deadly disease with median survival times of several months. Any treatment which can prolong patients' survival without causing severe side effects is of course an important addition to our limited arsenal in the fight against this disease. A recent article by Marikowsky and colleagues extended significantly our knowledge regarding the possible activity of disulfiram (well known in its commercial name Antabuse) as an anticancer agent (Marikowsky et al Int J of cancer 97 :34 2002). In this article it was demonstrated that disulfiram has potent antitumor activity and that it can act as a significant inhbitor of angiogenesis.

Since disulfiram has been well tolerated by thousands of patients, and there are observations that anti angiogenic therapy enhances the effect of chemotherapy (for example bevacizumab in combination with chemotherapy in colon carcinoma) we decided to conduct a clinical trial assessing the effect of the addition of this drug at moderate doses to chemotherapy which is used as one of the standard therapies in lung cancer. In order to obtain information regarding the effect of the addition of this drug, only 50% of the patients will be treated with the drug and the rest will be treated with placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine
Study Start Date : March 2006
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Disulfiram

Primary Outcome Measures :
  1. tumor response disease free survival survival [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Clinical response
  2. treatment tolerance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic non-small cell lung cancer
  • Previously untreated
  • ECOG performance status (PS) 0-1
  • Liver function tests within the norm

Exclusion Criteria:

  • Over 18
  • Willingness to abstain from alcohol
  • Not pregnant
  • Without a psychiatric history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00312819

Layout table for location information
Oncology Institute Meir Medical Center
Kfar Saba, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Augusta Hospital, Berlin
Layout table for investigator information
Principal Investigator: Hovav Nechushtan, MD, PhD Hadassah Medical Center Ein Kerem
Study Chair: Nili Peylan-Ramu, MD Hadassah Ein Kerem Medical Center
Study Chair: Maya Gotfrid, MD Meir Medical Center Kfar Saba

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: hovav nechushtan, HadassahHMO Identifier: NCT00312819     History of Changes
Other Study ID Numbers: DVC1.03-HMO-CTIL
First Posted: April 11, 2006    Key Record Dates
Last Update Posted: August 31, 2010
Last Verified: February 2009
Keywords provided by Hadassah Medical Organization:
Non-small cel lung cancer
randomized phaseII
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Alcohol Deterrents
Acetaldehyde Dehydrogenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action